TrialCancer2008

Phase 3, randomized, controlled trial of atrasentan in patients with nonmetastatic, hormone-refractory prostate cancer.

Joel B Nelson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.